Analysts hail Akero's midphase NASH data as best in class

Akero Therapeutics has shared more results from a phase 2a trial of its nonalcoholic steatohepatitis (NASH) prospect efruxifermin. The trial found half of biopsied participants experienced a one-stage or greater improvement in fibrosis, prompting Jefferies analysts to hail the data as best in class and sending Akero’s share price soaring.